In the last trading session, 1.42 million AlloVir Inc (NASDAQ:ALVR) shares changed hands as the company’s beta touched 0.91. With the company’s per share price at $1.63 changed hands at -$0.02 or -1.21% during last session, the market valuation stood at $185.92M. ALVR’s last price was a discount, traded about -380.98% off its 52-week high of $7.84. The share price had its 52-week low at $1.31, which suggests the last value was 19.63% up since then. When we look at AlloVir Inc’s average trading volume, we note the 10-day average is 0.94 million shares, with the 3-month average coming to 904.93K.
Analysts gave the AlloVir Inc (ALVR) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ALVR as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. AlloVir Inc’s EPS for the current quarter is expected to be -$0.4.
AlloVir Inc (NASDAQ:ALVR) trade information
Instantly ALVR was in red as seen at the end of in last trading. With action 14.79%, the performance over the past five days has been green. The drop to weekly highs of 1.7750 on Friday, 11/17/23 subtracted -1.21% to the stock’s daily price. The company’s shares are showing year-to-date downside of -68.23%, with the 5-day performance at 14.79% in the green. However, in the 30-day time frame, AlloVir Inc (NASDAQ:ALVR) is 3.82% up. Looking at the short shares, we see there were 11.33 million shares sold at short interest cover period of 18.97 days.
The consensus price target for the stock as assigned by Wall Street analysts is $19.50, meaning bulls need an upside of 91.64% from its current market value. According to analyst projections, ALVR’s forecast low is $14.00 with $27.00 as the target high. To hit the forecast high, the stock’s price needs a -1556.44% plunge from its current level, while the stock would need to soar -758.9% for it to hit the projected low.
AlloVir Inc (ALVR) estimates and forecasts
Data shows that the AlloVir Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -61.10% over the past 6 months, a 22.27% in annual growth rate that is considerably higher than the industry average of 11.30%. Moreover, analysts have looked to lower expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for AlloVir Inc will fall -8.10%, while the growth in revenue is estimated to hit -6.80% for the next quarter.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -104.72%. The 2023 estimates are for AlloVir Inc earnings to increase by 22.12%.
AlloVir Inc is expected to release its next quarterly earnings report between February 13 and February 19.
AlloVir Inc (NASDAQ:ALVR)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 49.35% of AlloVir Inc shares while 35.14% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 69.38%. There are 35.14% institutions holding the AlloVir Inc stock share, with FMR, LLC the top institutional holder. As of Jun 29, 2023, the company held 8.35% of the shares, roughly 9.52 million ALVR shares worth $32.37 million.
Wasatch Advisors LP holds the second largest percentage of outstanding shares, with 5.83% or 6.64 million shares worth $22.59 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Aug 30, 2023 were Fidelity Growth Company Fund and Wasatch Small Cap Growth Fund. With 2.7 million shares estimated at $8.47 million under it, the former controlled 2.37% of total outstanding shares. On the other hand, Wasatch Small Cap Growth Fund held about 2.15% of the shares, roughly 2.46 million shares worth around $8.35 million.